---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-038778"
form_type: "8-K"
ticker: "TOVX"
cik: "0000894158"
company_name: "Theriva Biologics, Inc."
filed_at: "2023-03-30T23:59:59+00:00"
generated_at: "2026-06-17T09:54:47.557292+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Theriva Biologics reports $41.8M cash, Q4 2022 results; VCN-01 trials advance

## Summary
- Cash and equivalents $41.8M as of Dec 31, 2022, down from $67.3M; runway into Q3 2024.
- G&A expenses $9.9M (+50.8% YoY); R&D expenses $11.7M (+50% YoY) driven by VCN-01 trials.
- First patient dosed in VIRAGE Phase 2b trial of VCN-01 for metastatic pancreatic cancer (Jan 2023).
- First patient dosed in investigator-sponsored Phase 1 trial of VCN-01 for brain tumors (Jan 2023).
- SYN-004 Phase 1b/2a in allo-HCT: blinded safety/PK data presented at Tandem Meetings (Feb 2023).

## SEC filing metadata
- accession: 0001104659-23-038778
- form_type: 8-K
- ticker: TOVX
- cik: 0000894158
- company_name: Theriva Biologics, Inc.
- filed_at: 2023-03-30T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/894158/000110465923038778/0001104659-23-038778-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/894158/000110465923038778/tm2310776d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-038778
- JSON: https://secwatch.observer/filing/0001104659-23-038778.json
- Plain text: https://secwatch.observer/filing/0001104659-23-038778.txt

## Key facts
- Earnings Releases
  Theriva Biologics, Inc. reported financial results for the fourth quarter and year ended December 31, 2022.
  - Period: the fourth quarter and year ended December 31, 2022
  - Result: reported results
  source text: On March 30, 2023, Theriva Biologics, Inc., a Delaware corporation (the “Company”), issued a press release announcing its financial results for the fourth quarter and year ended December 31, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/894158/000110465923038778/0001104659-23-038778-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.